Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 45 Products per page

Stelara
Read More
Stelara (ustekinumab; Johnson & Johnson/Mitsubishi Tanabe) is a high-affinity, fully human monoclonal antibody that targets the p40 subunit of cytokines interleukin (IL)-12 and IL-23 proteins that occur in the immune system.
August 2, 2018
Find out more
Trumenba
Read More
Trumenba (Pfizer) is a bivalent recombinant meningococcal serogroup B vaccine indicated for immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals aged 10−25 years in the US. Trumenba is a sterile suspension composed of two recombinant lapidated factor H binding protein variants. Factor H binding protein is found on the surface of meningococci and enhances the bacterium’s ability to avoid host defense.
September 3, 2019
Find out more
Japan Pharma Outlook

$3,000.00

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.
September 28, 2016
Find out more
Disease Analysis: Anemia in Chronic Kidney Disease
Read More
Anemia in chronic kidney disease (CKD), defined as a reduction in red blood cells (RBCs) or hemoglobin levels, often results from decreased levels of erythropoietin and increased levels of hepcidin. Erythropoietin is primarily produced in the kidneys and increases the production of RBCs by acting on precursor cells. H
November 17, 2022
Find out more
Disease Analysis: Migraine
Read More
Migraine is a common, disabling, and recurring neurological disorder characterized by severe headache co-occurring with nausea, vomiting, and other symptoms, the duration of which can range from hours to days.
November 2, 2022
Find out more
Market Spotlight: Migraine

$1,318.00

This Market Spotlight report covers the migraine market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
August 17, 2020
Find out more
Market Spotlight: Esophageal Cancer

$1,318.00

This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
September 15, 2022
Find out more
Gilotrif
Read More
Gilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4.
August 30, 2018
Find out more
LT-02
Read More
LT-02 (Lipid Therapeutics/Dr Falk) is a modified-release formulation of phosphatidylcholine that is in Phase III development for the treatment of ulcerative colitis.
May 9, 2017
Find out more
Abilify/Abilify Maintena
Read More
Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor.
March 29, 2019
Find out more
Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for PVD therapeutic devices; these include percutaneous transluminal angioplasty devices, vascular stents, atherectomy devices, thrombectomy devices, and chronic total occlusion crossing devices.
September 22, 2022
Find out more
Market Spotlight: Eating Disorders

$1,318.00

This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
October 6, 2022
Find out more
lefitolimod
Read More
Lefitolimod is a synthetic DNA-based immunomodulator that acts as a Toll-like receptor (TLR)9 agonist.
December 11, 2017
Find out more
Erdafitinib
Read More
Erdafitinib (Johnson & Johnson/Otsuka) is a small molecule inhibitor that targets fibroblast growth factor receptors (FGFRs), which play a role in the angiogenesis pathway, facilitating tumor growth and metastasis.
July 4, 2017
Find out more
US Neurointerventional Devices Market

$4,750.00

Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain. Neurointerventional devices, which contributed sales of more than $870m in the US in 2015, involve a variety of standard and application-specific transcatheter tools and techniques for the treatment of cerebrovascular pathologies (such as aneurysms, arteriovenous malformations [AVMs], and acute and chronic thromboembolic and atherosclerotic occlusions) that prompt clinically significant distortions of cerebral blood flow and carry a high risk of catastrophic breakdowns of cerebrovascular circulation manifested by hemorrhagic or ischemic stroke.
September 21, 2016
Find out more
Entyvio
Read More
Entyvio (vedolizumab; Takeda) is a humanized monoclonal antibody approved for the treatment of Crohn’s disease and ulcerative colitis.
August 2, 2018
Find out more
Datamonitor Axial Spondyloarthritis KOL Interviews

$599.00

Datamonitor interviewed three arthritis specialists, one based each in France, Italy and the US, to gauge their views on currently available treatment options, pipeline drugs, biosimilars and treatment challenges in axial spondyloarthritis (axSpA). The three interviews were combined into a single report.
March 9, 2017
Find out more
European Surgical Procedure Volumes: Orthopedic and Spine Procedures

$3,000.00

This report presents procedure volumes forecasts for some of the most common orthopedic and spine surgical procedures performed in the five EU countries of France, Germany, Italy, Spain, and the UK (5EU). The forecast period covered by this report is for the years 2016 through 2021.
December 7, 2017
Find out more
Gilenya
Read More
Gilenya is a synthetic derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb isaria sinclarii which acts as a potent agonist at four of the S1P receptors (S1P1, S1P3, S1P4, and S1P5).
November 24, 2017
Find out more
Dyslipidemia KOL Insight Interview #2

$599.00

Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.
July 28, 2014
Find out more
Bax 817
Read More
BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…
March 14, 2016
Find out more
INOpulse
Read More
INOpulse (Bellerophon Therapeutics) is a drug-device combination being developed to deliver a continuous, pulsed dose of nitric oxide via intranasal inhalation.
October 29, 2018
Find out more
Toca 511/FC
Read More
Toca 511 (vocimagene amiretrorepvec) and Toca FC (5-fluorocytosine) are under investigation as a
combination therapy for use in recurrent high-grade gliomas, including GBM. Toca 511 is an
injectable retroviral replicating vector that encodes the prodrug activator enzyme cytosine deaminase
(CD), which is derived from yeast and not found in the human genome
April 13, 2016
Find out more
Zyvox
Read More
Pfizer developed Zyvox (linezolid) as the first oxazolidinone antimicrobial agent. The drug gained its first regulatory approval for the treatment of complicated skin and skin structure infections (cSSSI) in the US market in 2000.
June 19, 2015
Find out more
Vosevi
Read More
Vosevi ([sofosbuvir + velpatasvir + voxilaprevir]) is Gilead’s third-generation, pan-genotypic, interferon-free regimen. The fixed-dose combination contains the hepatitis C virus nucleotide NS5B inhibitor sofosbuvir, a second-generation NS5A inhibitor (velpatasvir), and the company’s NS3 protease inhibitor (voxilaprevir).
November 6, 2017
Find out more
When Deals Go Wrong: Lessons from Failure

$2,995.00

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Yet a look back at prior years’ eye-popping deal sums reveals many billions of dollars of write-offs and lost value. Key assets failed or disappointed in at least half of 2014’s largest acquisitions and licensing deals. Failure is part of the drug discovery landscape, but some lessons can be learned from dud deals.

July 12, 2019
Find out more
Breast Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies across all three subtypes of breast cancer. Key pipeline assets highlighted include Enhertu, Trodelvy, Tecentriq, and enobosarm.
July 29, 2022
Find out more
Zinbryta
Read More
Zinbryta is a humanized monoclonal antibody that selectively binds to the alpha chain (cluster of differentiation [CD]25) of the interleukin-2 receptor on activated T cells to prevent the immunoactivation of MS.
November 24, 2017
Find out more
Dermatology KOL Interview

$599.00

BioMedTracker – Dermatology KOL Interview In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.
October 31, 2014
Find out more
Remodulin
Read More
Remodulin (treprostinil; United Therapeutics/Antigen/Mochida) is a prostaglandin analog that functions as a prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
Sovaldi
Read More
Sovaldi (sofosbuvir; Gilead) was the first interferon-free regimen to be approved for genotype 2/3 (GT-

2/3) patients, and has greatly benefited from the lucrative warehoused population and lack of

competitors in this subgroup.
November 6, 2017
Find out more
Market Spotlight: Mantle Cell Lymphoma

$1,318.00

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
August 25, 2022
Find out more
umbralisib
Read More
Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies.
January 30, 2019
Find out more
Market Spotlight: Venous Thromboembolism (VTE)

$1,318.00

This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
October 6, 2022
Find out more
Disease Analysis: HR+/HER2- Breast Cancer
Read More
Hormone receptor-positive (HR+) is the most common breast cancer subtype, with approximately 70% of breast cancers presenting with overexpression of estrogen receptors, progesterone receptors, or both (De Placido and Pronzato, 2015). Overexpression of the hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
November 11, 2022
Find out more
Wet Age-Related Macular Degeneration (Wet AMD) KOL Interview – US #1

$599.00

A US-based KOL opines about various biologics currently in use in clinical practice. During the discussion, the KOL speaks about their views on the safety and durability of currently approved agents, the newer modes of administration, and the role of each approved agent in the treatment armamentarium.
September 29, 2022
Find out more
Ophthalmic Surgical Products Market

$4,750.00

At $9.1bn, the ophthalmic surgical products market is one of the largest medical device markets globally, and serves an important need: preventing blindness for millions of people who suffer from cataracts, glaucoma, vitreoretinal disease, and refractive errors.
December 8, 2021
Find out more
Disease Analysis: Type 1 Diabetes
Read More
Diabetes mellitus is a group of chronic endocrine disorders characterized by hyperglycemia due to insufficient levels or action of insulin, a hormone responsible for regulating blood sugar. Symptoms include excessive excretion of urine (polyuria), thirst (polydipsia), constant hunger, weight loss, vision changes, and fatigue. In the long term, the disease can also cause disabling and lifethreatening complications such as cardiovascular disease (CVD), nerve damage (neuropathy, which along with peripheral vascular disease can lead to amputations), kidney damage (nephropathy), and eye disease (leading to retinopathy, loss of vision, and potentially blindness). If untreated, life-threatening conditions can develop, including diabetic ketoacidosis (DKA), particularly in type 1 diabetes, and the hyperosmolar hyperglycemic state in type 2 diabetes
October 10, 2022
Find out more
Zeftera
Read More
Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) is a novel intravenous broad-spectrum fifth-generation cephalosporin.
June 19, 2015
Find out more
General and Pelvic Endoscopic Surgery Devices Market

$4,750.00

This report provides an in-depth analysis of the global market for medical devices used in endoscopic general and pelvic surgeries.

Medical devices covered in this report include:

> access devices
> access site closure devices
> ancillary devices
> endoscopes
> hand instruments
> insufflation products.

This report provides the following useful information:

> medical device product portfolios offered by leading manufacturers
> procedure volumes for endoscopic general and pelvic surgeries
> top-selling products, as well as emerging new products
> in-depth market and competitive analysis
June 12, 2017
Find out more
esuberaprost
Read More
Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
October 29, 2018
Find out more
Seviprotimut-L
Read More
Seviprotimut-L (Polynoma/CK Life Sciences) is a polyvalent, shed-antigen vaccine in development for the adjuvant treatment of Stage IIb–III melanoma patients. Seviprotimut-L contains a combination of antigens from three proprietary melanoma cell lines, and is intended to stimulate the body’s immune system to fight cancer.
May 23, 2018
Find out more
Market Spotlight: Sjögren’s Syndrome

$1,318.00

This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.
July 26, 2022
Find out more
Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

$599.00

Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.
August 28, 2020
Find out more
Disease Analysis: Psoriasis
Read More
First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive, systemic therapies will continue to be relegated to more severe psoriasis.
November 7, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *